Nothing Special   »   [go: up one dir, main page]

SG10201913948PA - Engineered target specific nucleases - Google Patents

Engineered target specific nucleases

Info

Publication number
SG10201913948PA
SG10201913948PA SG10201913948PA SG10201913948PA SG10201913948PA SG 10201913948P A SG10201913948P A SG 10201913948PA SG 10201913948P A SG10201913948P A SG 10201913948PA SG 10201913948P A SG10201913948P A SG 10201913948PA SG 10201913948P A SG10201913948P A SG 10201913948PA
Authority
SG
Singapore
Prior art keywords
target specific
specific nucleases
engineered target
engineered
nucleases
Prior art date
Application number
SG10201913948PA
Inventor
Jeffrey C Miller
Edward J Rebar
Original Assignee
Sangamo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Therapeutics Inc filed Critical Sangamo Therapeutics Inc
Publication of SG10201913948PA publication Critical patent/SG10201913948PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
SG10201913948PA 2016-08-24 2017-08-24 Engineered target specific nucleases SG10201913948PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378978P 2016-08-24 2016-08-24
US201762443981P 2017-01-09 2017-01-09

Publications (1)

Publication Number Publication Date
SG10201913948PA true SG10201913948PA (en) 2020-03-30

Family

ID=61246273

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201901364VA SG11201901364VA (en) 2016-08-24 2017-08-24 Engineered target specific nucleases
SG10202007392SA SG10202007392SA (en) 2016-08-24 2017-08-24 Engineered target specific nucleases
SG10201913948PA SG10201913948PA (en) 2016-08-24 2017-08-24 Engineered target specific nucleases

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG11201901364VA SG11201901364VA (en) 2016-08-24 2017-08-24 Engineered target specific nucleases
SG10202007392SA SG10202007392SA (en) 2016-08-24 2017-08-24 Engineered target specific nucleases

Country Status (12)

Country Link
US (5) US10975393B2 (en)
EP (2) EP3964573A1 (en)
JP (2) JP7272948B2 (en)
KR (3) KR102455249B1 (en)
CN (1) CN110418841A (en)
AU (2) AU2017315414B2 (en)
BR (1) BR112019003327A2 (en)
CA (1) CA3034884A1 (en)
ES (1) ES2901989T3 (en)
IL (2) IL300783A (en)
SG (3) SG11201901364VA (en)
WO (1) WO2018039448A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
NO2718257T3 (en) * 2014-05-30 2018-04-14
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
KR20230095129A (en) 2016-08-03 2023-06-28 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Adenosine nucleobase editors and uses thereof
CN109804066A (en) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 Programmable CAS9- recombination enzyme fusion proteins and application thereof
PE20190568A1 (en) 2016-08-24 2019-04-22 Sangamo Therapeutics Inc REGULATION OF GENE EXPRESSION USING MODIFIED NUCLEASES
WO2018039448A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Engineered target specific nucleases
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
JP7256739B2 (en) 2016-09-07 2023-04-12 サンガモ セラピューティクス， インコーポレイテッド Modulation of liver genes
GB2573062A (en) 2016-10-14 2019-10-23 Harvard College AAV delivery of nucleobase editors
KR102712926B1 (en) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for the treatment of Fabry disease
US11020492B2 (en) 2016-10-31 2021-06-01 Sangamo Therapeutics, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
JP7292204B2 (en) 2016-12-01 2023-06-16 サンガモ セラピューティクス， インコーポレイテッド Tau modulators and methods and compositions for their delivery
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
TW201839136A (en) 2017-02-06 2018-11-01 瑞士商諾華公司 Compositions and methods for the treatment of hemoglobinopathies
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
EP3592777A1 (en) 2017-03-10 2020-01-15 President and Fellows of Harvard College Cytosine to guanine base editor
BR112019019655A2 (en) 2017-03-23 2020-04-22 Harvard College nucleobase editors comprising nucleic acid programmable dna binding proteins
EP4410317A3 (en) 2017-04-28 2024-10-30 Acuitas Therapeutics Inc. Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
AU2018261366A1 (en) 2017-05-03 2019-10-31 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CTFR) gene
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
JP2020534795A (en) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ Methods and Compositions for Evolving Base Editing Factors Using Phage-Supported Continuous Evolution (PACE)
EP3676376A2 (en) 2017-08-30 2020-07-08 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20200121782A (en) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 Uses of adenosine base editor
SG11202004003YA (en) 2017-11-09 2020-05-28 Sangamo Therapeutics Inc Genetic modification of cytokine inducible sh2-containing protein (cish) gene
KR20200118468A (en) 2018-02-08 2020-10-15 상가모 테라퓨틱스, 인코포레이티드 Engineered target specific nuclease
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2020006131A2 (en) * 2018-06-27 2020-01-02 Altius Institute For Biomedical Sciences Nucleases for genome editing
KR102712986B1 (en) 2018-08-23 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 Engineered target-specific base editor
AU2019333722A1 (en) * 2018-08-27 2021-04-15 Hiroshima University Novel nuclease domain and uses thereof
WO2020061161A1 (en) * 2018-09-18 2020-03-26 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
DK3908568T3 (en) 2019-01-11 2024-08-26 Acuitas Therapeutics Inc Lipids for lipid nanoparticle delivery of active substances
EP3826664A4 (en) 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
WO2020191245A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
AU2020253362A1 (en) 2019-04-02 2021-11-04 Sangamo Therapeutics, Inc. Methods for the treatment of beta-thalassemia
SG11202111443SA (en) 2019-04-23 2021-11-29 Sangamo Therapeutics Inc Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
AU2020279370A1 (en) 2019-05-21 2021-12-16 Sangamo Therapeutics, Inc. Controlled transgene expression in regulatory T cells
KR20220071248A (en) 2019-10-02 2022-05-31 상가모 테라퓨틱스, 인코포레이티드 Zinc finger protein transcription factor to inhibit alpha-synuclein expression
WO2021067864A1 (en) 2019-10-02 2021-04-08 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for treatment of prion disease
US20210130828A1 (en) 2019-11-01 2021-05-06 Sangamo Therapeutics, Inc. Gin recombinase variants
CN115279419A (en) 2019-11-01 2022-11-01 美商圣加莫治疗股份有限公司 Compositions and methods for genome engineering
AR121118A1 (en) 2020-01-22 2022-04-20 Sangamo Therapeutics Inc ZINC FINGER PROTEIN TRANSCRIPTION FACTORS TO REPRESS TAU EXPRESSION
KR20230019843A (en) 2020-05-08 2023-02-09 더 브로드 인스티튜트, 인코퍼레이티드 Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN116096702A (en) 2020-07-16 2023-05-09 爱康泰生治疗公司 Cationic lipids for lipid nanoparticles
WO2022046760A2 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
CA3196599A1 (en) 2020-09-25 2022-03-31 Sangamo Therapeutics, Inc. Zinc finger fusion proteins for nucleobase editing
JP2023545972A (en) 2020-10-02 2023-11-01 サンガモ セラピューティクス， インコーポレイテッド Novel zinc finger protein transcription factor to suppress alpha-synuclein expression
JPWO2022097663A1 (en) * 2020-11-06 2022-05-12
CN113308451B (en) * 2020-12-07 2023-07-25 中国科学院动物研究所 Engineered Cas effector proteins and methods of use thereof
CN112680431B (en) * 2021-03-22 2021-06-11 吴江近岸蛋白质科技有限公司 DNA library preparation method based on fragmenting enzyme
CN113293165B (en) * 2021-06-21 2022-11-15 军事科学院军事医学研究院环境医学与作业医学研究所 HEV specific crRNA based on CRISPR-Cas12a technology, detection kit and application thereof
EP4408995A1 (en) * 2021-09-28 2024-08-07 Acrigen Biosciences Compositions and methods for nucleic acid modifications
CN118647600A (en) 2021-12-16 2024-09-13 爱康泰生治疗公司 Lipids for lipid nanoparticle formulations
IL313758A (en) 2021-12-22 2024-08-01 Sangamo Therapeutics Inc Novel zinc finger fusion proteins for nucleobase editing
TW202413633A (en) * 2022-08-11 2024-04-01 美商敏達斯治療公司 Engineered immune cells expressing a car and a plurality of protein expression blockers and uses thereof
WO2024107861A2 (en) * 2022-11-16 2024-05-23 The Regents Of The University Of California Zinc finger engineering
WO2024116373A1 (en) * 2022-12-01 2024-06-06 国立大学法人広島大学 Nuclease domain for breaking dna into two strands

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5422251A (en) 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
ATE310812T1 (en) 1994-01-18 2005-12-15 Scripps Research Inst DERIVATIVES OF ZINC FINGER PROTEINS AND METHODS
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
ATE410518T1 (en) 1994-03-23 2008-10-15 Univ Ohio COMPACT NUCLEIC ACID AND ITS ADMINISTRATION IN CELLS
USRE45795E1 (en) 1994-08-20 2015-11-10 Gendaq, Ltd. Binding proteins for recognition of DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5928638A (en) 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
EP1060261B1 (en) 1998-03-02 2010-05-05 Massachusetts Institute of Technology Poly zinc finger proteins with improved linkers
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7257541B1 (en) 1999-10-08 2007-08-14 I2 Technologies Us, Inc. System and method for performing a business process in a multi-enterprise, collaborating network
IL150069A0 (en) 1999-12-06 2002-12-01 Sangamo Biosciences Inc Methods of using randomized libraries of zinc finger proteins for the identification of gene function
ATE483970T1 (en) 2000-02-08 2010-10-15 Sangamo Biosciences Inc CELLS FOR DRUG DISCOVERY
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
CA2407745C (en) 2000-04-28 2011-11-22 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
AU2001253914B2 (en) 2000-04-28 2006-06-08 Sangamo Therapeutics, Inc. Targeted modification of chromatin structure
US7923542B2 (en) 2000-04-28 2011-04-12 Sangamo Biosciences, Inc. Libraries of regulatory sequences, methods of making and using same
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
JP2002060786A (en) 2000-08-23 2002-02-26 Kao Corp Germicidal stainproofing agent for hard surface
US6919204B2 (en) 2000-09-29 2005-07-19 Sangamo Biosciences, Inc. Modulation of gene expression using localization domains
WO2002044376A2 (en) 2000-11-28 2002-06-06 Sangamo Biosciences, Inc. Modulation of gene expression using insulator binding proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
EP1353941B1 (en) * 2001-01-22 2013-03-13 Sangamo BioSciences, Inc. Modified zinc finger binding proteins
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
AU2002336373A1 (en) 2001-08-20 2003-03-03 The Scripps Research Institute Zinc finger binding domains for cnn
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
US7271002B2 (en) 2001-11-09 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of adeno-associated virus in insect cells
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
JP4968498B2 (en) 2002-01-23 2012-07-04 ユニバーシティ オブ ユタ リサーチ ファウンデーション Targeted chromosomal mutagenesis using zinc finger nuclease
AU2003215869B2 (en) 2002-03-15 2008-04-24 Cellectis Hybrid and single chain meganucleases and use thereof
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
CA2514417A1 (en) 2003-01-28 2004-08-12 Cellectis Custom-made meganuclease and use thereof
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1732614B1 (en) 2004-04-08 2008-12-24 Sangamo Biosciences Inc. Compositions for treating neuropathic and neurodegenerative conditions
CA2562193A1 (en) 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Treatment of neuropathic pain with zinc finger proteins
US20060063231A1 (en) 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
US20090068164A1 (en) 2005-05-05 2009-03-12 The Ariz Bd Of Regents On Behald Of The Univ Of Az Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences
JP2009502170A (en) 2005-07-26 2009-01-29 サンガモ バイオサイエンシズ インコーポレイテッド Targeted integration and expression of foreign nucleic acid sequences
US20090263900A1 (en) 2008-04-14 2009-10-22 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
EP2628794B1 (en) 2005-10-18 2016-05-04 Precision Biosciences Rationally designed meganucleases with altered sequence specificity and DNA-binding affinity
EP2213731B1 (en) 2006-05-25 2013-12-04 Sangamo BioSciences, Inc. Variant foki cleavage half-domains
ATE536371T1 (en) 2006-05-25 2011-12-15 Sangamo Biosciences Inc METHOD AND COMPOSITIONS FOR GENE DEACTIVATION
CN101528924B (en) * 2006-08-11 2015-11-25 陶氏益农公司 Zinc finger nuclease-mediated homologous recombination
AU2008244473B2 (en) 2007-04-26 2013-06-20 Sangamo Therapeutics, Inc. Targeted integration into the PPP1R12C locus
AU2008265683B2 (en) 2007-06-19 2013-08-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
CN101883863B (en) 2007-09-27 2018-01-23 桑格摩生物科学股份有限公司 The rapid in vivo identification of biologically active nucleases
RU2499599C2 (en) 2007-09-28 2013-11-27 Интрексон Корпорейшн Therapeutic gene switching constructs and bioreactors for expressing biotherapeutic molecules and using them
JP2011521643A (en) 2008-05-28 2011-07-28 サンガモ バイオサイエンシーズ， インコーポレイテッド Composition for linking a DNA binding domain and a cleavage domain
EP2294191B1 (en) 2008-06-10 2016-09-28 Sangamo BioSciences, Inc. Methods and compositions for generation of bax- and bak-deficient cell lines
US8703489B2 (en) 2008-08-22 2014-04-22 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
PT2334794T (en) 2008-09-15 2017-02-15 Harvard College Modulation of bcl11a for treatment of hemoglobinopathies
US9206404B2 (en) 2008-12-04 2015-12-08 Sangamo Biosciences, Inc. Method of deleting an IgM gene in an isolated rat cell
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
EP3581197A1 (en) 2009-07-31 2019-12-18 ethris GmbH Rna with a combination of unmodified and modified nucleotides for protein expression
US8961281B2 (en) 2009-09-28 2015-02-24 Entsorgafin S.P.A. Ventilation group for flow reversal
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
BR112012012444A2 (en) * 2009-11-27 2015-09-22 Basf Plant Science Co Gmbh "chimeric endonuclease, isolated polynucleotide, expression cassette, vector, non-human organism, method for providing a chimeric endonuclease, method for homologous polynucleotide recombination, method for targeted polynucleotide mutation, and method for homologous recombination or targeted mutation"
PL2816112T3 (en) 2009-12-10 2019-03-29 Regents Of The University Of Minnesota Tal effector-mediated DNA modification
AU2011209743B2 (en) 2010-01-28 2016-03-10 The Children's Hospital Of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
EP2615106B1 (en) 2010-02-08 2018-04-25 Sangamo Therapeutics, Inc. Engineered cleavage half-domains
WO2011100058A1 (en) 2010-02-09 2011-08-18 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
HUE048072T2 (en) 2010-05-03 2020-05-28 Sangamo Therapeutics Inc Compositions for linking zinc finger modules
AU2011256838B2 (en) * 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
WO2012012667A2 (en) 2010-07-21 2012-01-26 Sangamo Biosciences, Inc. Methods and compositions for modification of a hla locus
US9057057B2 (en) 2010-07-27 2015-06-16 The Johns Hopkins University Obligate heterodimer variants of foki cleavage domain
GB201014169D0 (en) 2010-08-25 2010-10-06 Cambridge Entpr Ltd In vitro hepatic differentiation
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
EP2758529B1 (en) 2011-09-21 2019-03-20 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression
CA2852955C (en) 2011-10-27 2021-02-16 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
AU2012340213B2 (en) 2011-11-16 2017-12-07 Sangamo Therapeutics, Inc. Modified DNA-binding proteins and uses thereof
JP6559063B2 (en) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for nuclease-mediated targeted integration of transgenes
EA201492222A1 (en) * 2012-05-25 2015-05-29 Селлектис METHODS OF CONSTRUCTING NONALLOACTIVE AND SUSTAINABLE T-CELL IMMUNOSUPRESSION FOR IMMUNOTHERAPY
PT2890780T (en) 2012-08-29 2020-08-03 Sangamo Therapeutics Inc Methods and compositions for treatment of a genetic condition
AU2013329186B2 (en) 2012-10-10 2019-02-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
JP2016500254A (en) 2012-12-05 2016-01-12 サンガモ バイオサイエンシーズ， インコーポレイテッド Methods and compositions for the regulation of metabolic diseases
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014097113A2 (en) 2012-12-18 2014-06-26 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
ES2713503T3 (en) 2013-03-15 2019-05-22 Massachusetts Gen Hospital Use of RNA-guided FOKI nucleases (RFN) to increase the specificity for editing the RNA-guided genome
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
KR102220382B1 (en) * 2013-05-13 2021-02-25 셀렉티스 Methods for engineering highly active t cell for immunotherapy
EP2997146A4 (en) 2013-05-15 2017-04-26 Sangamo BioSciences, Inc. Methods and compositions for treatment of a genetic condition
CA3131284C (en) 2013-08-28 2023-09-19 David Paschon Compositions for linking dna-binding domains and cleavage domains
EP3058072B1 (en) 2013-10-17 2021-05-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
PL3492593T3 (en) 2013-11-13 2022-04-19 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
JP6535684B2 (en) 2013-12-09 2019-06-26 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for genome manipulation
BR112016025519A2 (en) 2014-05-01 2018-01-16 Univ Washington in vivo genetic engineering with adenovirus vectors
EP3139966B1 (en) 2014-05-08 2020-11-18 Sangamo Therapeutics, Inc. Compositions for use in treating huntington's disease
US9816074B2 (en) 2014-07-25 2017-11-14 Sangamo Therapeutics, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US9616090B2 (en) 2014-07-30 2017-04-11 Sangamo Biosciences, Inc. Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
MX2017014446A (en) 2015-05-12 2018-06-13 Sangamo Therapeutics Inc Nuclease-mediated regulation of gene expression.
CN108024544B (en) * 2015-07-13 2022-04-29 桑格摩生物治疗股份有限公司 Delivery methods and compositions for nuclease-mediated genome engineering
JP7128741B2 (en) 2015-12-18 2022-08-31 サンガモ セラピューティクス， インコーポレイテッド Targeted disruption of T-cell receptors
US10724020B2 (en) 2016-02-02 2020-07-28 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
PE20190568A1 (en) 2016-08-24 2019-04-22 Sangamo Therapeutics Inc REGULATION OF GENE EXPRESSION USING MODIFIED NUCLEASES
WO2018039448A1 (en) 2016-08-24 2018-03-01 Sangamo Therapeutics, Inc. Engineered target specific nucleases
WO2018107026A1 (en) 2016-12-09 2018-06-14 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
IL272302B1 (en) * 2017-08-08 2024-09-01 Sangamo Therapeutics Inc Chimeric antigen receptor mediated genetically modified t cell targeting

Also Published As

Publication number Publication date
CA3034884A1 (en) 2018-03-01
KR102455249B1 (en) 2022-10-17
AU2017315414A1 (en) 2019-03-14
ES2901989T3 (en) 2022-03-24
AU2017315414B2 (en) 2024-02-15
US20240229079A9 (en) 2024-07-11
US20180087072A1 (en) 2018-03-29
CN110418841A (en) 2019-11-05
EP3504327A4 (en) 2020-02-12
JP2023100751A (en) 2023-07-19
SG11201901364VA (en) 2019-03-28
EP3504327A1 (en) 2019-07-03
JP7272948B2 (en) 2023-05-12
BR112019003327A2 (en) 2019-07-02
US20200340016A1 (en) 2020-10-29
AU2024203182A1 (en) 2024-08-01
AU2017315414A9 (en) 2019-07-18
KR20240144493A (en) 2024-10-02
US11827900B2 (en) 2023-11-28
JP2019528073A (en) 2019-10-10
RU2019108242A3 (en) 2021-04-09
RU2019108242A (en) 2020-09-25
IL264792B2 (en) 2023-10-01
US20210024957A1 (en) 2021-01-28
IL300783A (en) 2023-04-01
EP3964573A1 (en) 2022-03-09
EP3504327B1 (en) 2021-10-06
WO2018039448A1 (en) 2018-03-01
WO2018039448A9 (en) 2019-04-25
US20210024958A1 (en) 2021-01-28
KR20220145913A (en) 2022-10-31
US20240132917A1 (en) 2024-04-25
SG10202007392SA (en) 2020-09-29
US10975393B2 (en) 2021-04-13
AU2017315414A2 (en) 2020-03-12
IL264792B1 (en) 2023-06-01
IL264792A (en) 2019-03-31
KR20190039955A (en) 2019-04-16

Similar Documents

Publication Publication Date Title
SG10202007392SA (en) Engineered target specific nucleases
HK1257676A1 (en) Engineered crispr-cas9 nucleases
IL271342A (en) Nucleic acid-guided nucleases
IL276490A (en) Engineered target specific nucleases
IL254187A0 (en) Tgf-beta inhibitors
PL3504506T3 (en) Target
GB2540441B (en) Amplifiers
GB201501482D0 (en) Cost-effective tracking
DK3347540T3 (en) Bærer til et lineært loftspanel
GB201611925D0 (en) Cyclotron target
EP3353244A4 (en) Polymeric aminoacrylates
GB201515809D0 (en) Actuator
GB2536673B (en) Evaporator
GB201500242D0 (en) Projectile
IL257500A (en) Modified cullin1 gene
SG11201704051SA (en) Target assembly
GB201509204D0 (en) Improved tracking
GB201517270D0 (en) Target designator
FI20160292A (en) Target goal
GB201520386D0 (en) Actuator
SG11201700721QA (en) Target assembly
GB201503312D0 (en) Targets
GB2537392B (en) Improved evaporator
IL247839B (en) Muzzle
SG10201600814XA (en) Nuclease